273 related articles for article (PubMed ID: 30382588)
1. OCT4&SOX2-specific cytotoxic T lymphocytes plus programmed cell death protein 1 inhibitor presented with synergistic effect on killing lung cancer stem-like cells in vitro and treating drug-resistant lung cancer mice in vivo.
Zhang X; Hu F; Li C; Zheng X; Zhang B; Wang H; Tao G; Xu J; Zhang Y; Han B
J Cell Physiol; 2019 May; 234(5):6758-6768. PubMed ID: 30382588
[TBL] [Abstract][Full Text] [Related]
2. OCT4 and SOX2 Specific Cytotoxic T Cells Exhibit Not Only Good Efficiency but Also Synergize PD-1 Inhibitor (Nivolumab) in Treating Breast Cancer Stem-Like Cells and Drug-Resistant Breast Cancer Mice.
Peng W; Chang L; Li W; Liu Y; Zhang M
Front Oncol; 2022; 12():781093. PubMed ID: 35402219
[TBL] [Abstract][Full Text] [Related]
3. Antigen presentation of the Oct4 and Sox2 peptides by CD154-activated B lymphocytes enhances the killing effect of cytotoxic T lymphocytes on tumor stem-like cells derived from cisplatin-resistant lung cancer cells.
Zhang X; Zhang Y; Xu J; Wang H; Zheng X; Lou Y; Han B
J Cancer; 2018; 9(2):367-374. PubMed ID: 29344283
[TBL] [Abstract][Full Text] [Related]
4. Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells.
Kobayashi I; Takahashi F; Nurwidya F; Nara T; Hashimoto M; Murakami A; Yagishita S; Tajima K; Hidayat M; Shimada N; Suina K; Yoshioka Y; Sasaki S; Moriyama M; Moriyama H; Takahashi K
Biochem Biophys Res Commun; 2016 Apr; 473(1):125-132. PubMed ID: 26996130
[TBL] [Abstract][Full Text] [Related]
5. PGC-1α activator-induced fatty acid oxidation in tumor-infiltrating CTLs enhances effects of PD-1 blockade therapy in lung cancer.
Wan H; Xu B; Zhu N; Ren B
Tumori; 2020 Feb; 106(1):55-63. PubMed ID: 31451071
[TBL] [Abstract][Full Text] [Related]
6. Investigation of specific binding of designed oligodeoxynucleotide decoys to transcription factors in HT29 cell line undergoing epithelial-mesenchymal transition (EMT).
Bigdelou Z; Johari B; Kadivar M; Rismani E; Asadi Z; Rahmati M; Saltanatpour Z
J Cell Physiol; 2019 Dec; 234(12):22765-22774. PubMed ID: 31115051
[TBL] [Abstract][Full Text] [Related]
7. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
[TBL] [Abstract][Full Text] [Related]
8. β-catenin inhibitors suppress cells proliferation and promote cells apoptosis in PC9 lung cancer stem cells.
Zhang X; Zheng X; Lou Y; Wang H; Xu J; Zhang Y; Han B
Int J Clin Exp Pathol; 2017; 10(12):11968-11978. PubMed ID: 31966561
[TBL] [Abstract][Full Text] [Related]
9. Lung adenocarcinoma resistance to therapy with EGFR‑tyrosine kinase inhibitors is related to increased expression of cancer stem cell markers SOX2, OCT4 and NANOG.
Hu F; Li C; Zheng X; Zhang H; Shen Y; Zhou L; Yang X; Han B; Zhang X
Oncol Rep; 2020 Feb; 43(2):727-735. PubMed ID: 31894290
[TBL] [Abstract][Full Text] [Related]
10. [LincRNA-ROR functions as a ceRNA to regulate Oct4, Sox2, and Nanog expression by sponging miR-145 and its effect on biologic characteristics of colonic cancer stem cells].
Yan ZY; Sun XC
Zhonghua Bing Li Xue Za Zhi; 2018 Apr; 47(4):284-290. PubMed ID: 29690669
[No Abstract] [Full Text] [Related]
11. Tracking in vivo migration and distribution of antigen-specific cytotoxic T lymphocytes by 5,6-carboxyfluorescein diacetate succinimidyl ester staining during cancer immunotherapy.
Xu WL; Li SL; Wen M; Wen JY; Han J; Zhang HZ; Gao F; Cai JH
Chin Med J (Engl); 2013 Aug; 126(16):3019-25. PubMed ID: 23981604
[TBL] [Abstract][Full Text] [Related]
12. Crosstalks between Raf-kinase inhibitor protein and cancer stem cell transcription factors (Oct4, KLF4, Sox2, Nanog).
Lee S; Wottrich S; Bonavida B
Tumour Biol; 2017 Apr; 39(4):1010428317692253. PubMed ID: 28378634
[TBL] [Abstract][Full Text] [Related]
13. Yin Yang 1 is associated with cancer stem cell transcription factors (SOX2, OCT4, BMI1) and clinical implication.
Kaufhold S; Garbán H; Bonavida B
J Exp Clin Cancer Res; 2016 May; 35():84. PubMed ID: 27225481
[TBL] [Abstract][Full Text] [Related]
14. Galectin-3 modulates the EGFR signalling-mediated regulation of Sox2 expression via c-Myc in lung cancer.
Kuo HY; Hsu HT; Chen YC; Chang YW; Liu FT; Wu CW
Glycobiology; 2016 Feb; 26(2):155-65. PubMed ID: 26447186
[TBL] [Abstract][Full Text] [Related]
15. XIAP Limits Autophagic Degradation of Sox2 and Is A Therapeutic Target in Nasopharyngeal Carcinoma Stem Cells.
Ji J; Yu Y; Li ZL; Chen MY; Deng R; Huang X; Wang GF; Zhang MX; Yang Q; Ravichandran S; Feng GK; Xu XL; Yang CL; Qiu MZ; Jiao L; Yang D; Zhu XF
Theranostics; 2018; 8(6):1494-1510. PubMed ID: 29556337
[No Abstract] [Full Text] [Related]
16. Comparison of Cellular Transforming Activity of OCT4, NANOG, and SOX2 in Immortalized Astrocytes.
Seo S; Jeon HY; Kim H
DNA Cell Biol; 2017 Nov; 36(11):1000-1009. PubMed ID: 28933914
[TBL] [Abstract][Full Text] [Related]
17. Role of Oct4-Sox2 complex decoy oligodeoxynucleotides strategy on reverse epithelial to mesenchymal transition (EMT) induction in HT29-ShE encompassing enriched cancer stem-like cells.
Bigdelou Z; Mortazavi Y; Saltanatpour Z; Asadi Z; Kadivar M; Johari B
Mol Biol Rep; 2020 Mar; 47(3):1859-1869. PubMed ID: 32016633
[TBL] [Abstract][Full Text] [Related]
18. Correlation of Cancer Stem-Cell Markers OCT4, SOX2, and NANOG with Clinicopathological Features and Prognosis in Operative Patients with Rectal Cancer.
You L; Guo X; Huang Y
Yonsei Med J; 2018 Jan; 59(1):35-42. PubMed ID: 29214774
[TBL] [Abstract][Full Text] [Related]
19. Putative stemness markers octamer-binding transcription factor 4, sex-determining region Y-box 2, and NANOG in non-small cell lung carcinoma: A clinicopathological association.
Upadhyay VA; Shah KA; Makwana DP; Raval AP; Shah FD; Rawal RM
J Cancer Res Ther; 2020; 16(4):804-810. PubMed ID: 32930122
[TBL] [Abstract][Full Text] [Related]
20. Effects of Apatinib on the "Stemness" of Non-Small-Cell Lung Cancer Cells In Vivo and Its Related Mechanisms.
Yang B; Wang Y; Chen Z; Feng YM; Shi LL
Can Respir J; 2020; 2020():2479369. PubMed ID: 32849930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
